- Home
- LIXT vs DSS Comparison
LIXT vs DSS Comparison
Compare LIXT & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- DSS
- Stock Information
- Founded
- LIXT 2005
- DSS 1984
- Country
- LIXT United States
- DSS United States
- Employees
- LIXT N/A
- DSS N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- DSS Containers/Packaging
- Sector
- LIXT Health Care
- DSS Consumer Discretionary
- Exchange
- LIXT Nasdaq
- DSS Nasdaq
- Market Cap
- LIXT 6.3M
- DSS 7.3M
- IPO Year
- LIXT N/A
- DSS N/A
- Fundamental
- Price
- LIXT $1.27
- DSS $0.94
- Analyst Decision
- LIXT
- DSS
- Analyst Count
- LIXT 0
- DSS 0
- Target Price
- LIXT N/A
- DSS N/A
- AVG Volume (30 Days)
- LIXT 155.3K
- DSS 16.9K
- Earning Date
- LIXT 03-18-2025
- DSS 03-26-2025
- Dividend Yield
- LIXT N/A
- DSS N/A
- EPS Growth
- LIXT N/A
- DSS N/A
- EPS
- LIXT N/A
- DSS N/A
- Revenue
- LIXT N/A
- DSS $25,019,000.00
- Revenue This Year
- LIXT N/A
- DSS N/A
- Revenue Next Year
- LIXT N/A
- DSS N/A
- P/E Ratio
- LIXT N/A
- DSS N/A
- Revenue Growth
- LIXT N/A
- DSS N/A
- 52 Week Low
- LIXT $1.25
- DSS $0.77
- 52 Week High
- LIXT $4.40
- DSS $2.30
- Technical
- Relative Strength Index (RSI)
- LIXT 28.82
- DSS 55.12
- Support Level
- LIXT $1.35
- DSS $0.90
- Resistance Level
- LIXT $3.00
- DSS $0.96
- Average True Range (ATR)
- LIXT 0.26
- DSS 0.06
- MACD
- LIXT -0.13
- DSS 0.01
- Stochastic Oscillator
- LIXT 1.15
- DSS 76.96
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.